Prof. Dr. Murat Binbay'ın akademik çalışmaları — tam metinleri PDF olarak indirebilirsiniz.
The ArteraAI Prostate Test combines the digital image of the biopsy slide with the patient's clinical data to predict who will benefit from hormone therapy; the DIRECT-AI registry has begun measuring the test's effect in real practice.
An NHANES-based analysis published in The American Journal of Medicine found that men who obtain a larger share of their daily energy from ultra-processed foods have an approximately one-third higher risk of prostate cancer.
In biopsy-naive men with PI-RADS 2-3 findings, 68Ga-PSMA-11 PET/CT removed the need for biopsy in 49% of patients; non-inferiority in detecting significant cancer was met while insignificant cancer diagnosis fell by more than half.
A new analysis of the prospective TRUMPET registry of 1,028 patients showed that the way the disease first presents and a family history of prostate cancer are significantly associated with overall survival in mCRPC.
In the PRIMARY2 trial, PSMA PET/CT spared roughly half of men with equivocal MRI findings from biopsy; the detection of serious cancers was maintained while unnecessary diagnoses fell from 32% to 14%.
A JAMA analysis of National Cancer Database records from 2010-2023 revealed that 51% of focal therapies performed in prostate cancer were carried out in risk groups not supported by guidelines.
The TROP2-targeted antibody-drug conjugate datopotamab deruxtecan is being tested at phase 3 level, alone and combined with the PD-1/TIGIT bispecific antibody rilvegostomig, in high-risk MIUC patients after radical surgery.
The POISE-3 analysis covering 22 countries and 1,124 urological patients showed that tranexamic acid reduced major bleeding by 37% without significantly increasing thromboembolic events (European Urology, 2026).
High-resolution micro-ultrasound (29 MHz) images the prostate at tissue level and reveals lesions missed by MRI. What do the OPTIMUM trial and a 682-man screening series tell us?